These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27991698)

  • 1. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
    Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
    Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
    Zheng YB; Shang BY; Li Y; Zhen YS
    Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation.
    Sheng W; Gong J; Jiang M; Zhen Y
    Oncol Rep; 2017 Dec; 38(6):3507-3514. PubMed ID: 29130101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
    Zhang Q; Liu XJ; Hu L; Liao DS; Zheng YB; Zhen YS; Song X
    Int J Mol Med; 2012 Mar; 29(3):409-15. PubMed ID: 22108624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
    Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
    Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
    Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
    Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
    Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
    Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.
    Zhang Q; Liu X; Xu S; Li C; Zhang Y; Yang J; Zheng J
    Cancer Biother Radiopharm; 2012 Aug; 27(6):384-91. PubMed ID: 22651685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
    Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
    Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
    Seidi K; Jahanban-Esfahlan R; Monhemi H; Zare P; Minofar B; Daei Farshchi Adli A; Farajzadeh D; Behzadi R; Mesgari Abbasi M; Neubauer HA; Moriggl R; Zarghami N; Javaheri T
    Oncogene; 2018 Jul; 37(29):3967-3980. PubMed ID: 29662195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.
    Guo XF; Zhu XF; Yang WC; Zhang SH; Zhen YS
    PLoS One; 2014; 9(3):e92986. PubMed ID: 24664246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
    Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
    BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy.
    Xu J; Du Y; Liu XJ; Zhu BY; Zhang SH; Li L; Li Y; Wang XF; Shan CK; Wang RQ; Zhen YS
    Pharmacol Res; 2017 Dec; 126():66-76. PubMed ID: 28392461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
    Yokoyama Y; Ramakrishnan S
    Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13- tumor cells.
    Zhang Z; Hou L; Feng L; Huang S; Luo M; Shao S; Zhang X; Gu S; Zhao X
    Tumour Biol; 2015 Sep; 36(10):8167-75. PubMed ID: 25990455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
    Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
    Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
    Brand C; Greve B; Bölling T; Eich HT; Willich N; Harrach S; Hintelmann H; Lenz G; Mesters RM; Kessler T; Schliemann C; Berdel WE; Schwöppe C
    PLoS One; 2020; 15(2):e0229271. PubMed ID: 32084238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.